Price
Financials
Standalone, Rs crore| Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 48 | 43 | 51 | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Expenses | 21 | 47 | 42 | 50 | 43 | 74 | 124 | 104 | 66 | 22 | 24 | 89 |
| Operating Profit | 2 | 2 | 2 | 1 | 1 | 2 | -5 | -2 | -1 | -0 | 2 | 2 |
| OPM % | 7% | 3.4% | 3.8% | 2.1% | 2.3% | 2.4% | -4.2% | -2.0% | -1.8% | -1.2% | 7% | 2.4% |
| Other Income | 0 | 0 | 0 | 1 | 1 | 0 | 7 | 4 | 3 | 2 | 0 | 3 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Tax % | 25% | 33% | 24% | 31% | 31% | 15% | 32% | 34% | -11% | 69% | 22% | 26% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| EPS in Rs | 0.04 | 0.21 | 0.57 | 0.48 | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 | 0.60 | 3.45 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 61 | 80 | 90 | 97 | 106 | 94 | 71 | 94 | 120 | 221 | 89 | 116 |
| Expenses | 58 | 76 | 85 | 92 | 102 | 91 | 67 | 91 | 116 | 228 | 88 | 112 |
| Operating Profit | 3 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3 | -7 | 1 | 4 |
| OPM % | 4.9% | 4.3% | 4.9% | 4.7% | 4.3% | 3.3% | 5% | 3.0% | 2.8% | -3.2% | 0.7% | 3.3% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 11 | 3 | 3 |
| Interest | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 4 |
| Tax % | 39% | 51% | 27% | 33% | 22% | 26% | 32% | 27% | 22% | 33% | 26% | 26% |
| Net Profit | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 3 |
| EPS in Rs | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 4% | 10% | -1% | 31% | ||
| Compounded Profit Growth | 24% | 74% | 50% | 330% | ||
| Stock Price CAGR | % | -19% | -23% | 15% | ||
| Return on Equity | 5% | 5% | 6% | 10% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 6 | 6 | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 | 26 |
| Borrowings | 28 | 28 | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 21 | 17 |
| Other Liabilities | 8 | 10 | 26 | 28 | 37 | 19 | 19 | 25 | 14 | 56 | 51 | 45 |
| Total Liabilities | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| Fixed Assets | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 41 | 44 | 51 | 56 | 78 | 74 | 71 | 72 | 60 | 99 | 99 | 90 |
| Total Assets | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | -6 | 9 |
| Cash from Investing Activity | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -2 | -1 | -0 |
| Cash from Financing Activity | 0 | 0 | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | 2 | -6 |
| Net Cash Flow | 0 | 0 | -1 | -0 | -0 | -0 | 2 | 3 | 1 | -1 | -4 | 2 |
| Free Cash Flow | 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 4 | -6 | 8 |
| CFO/OP | 0% | 0% | -200% | -129% | 98% | -238% | 229% | 440% | 164% | -94% | -805% | 250% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 66 | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 | 148 | 171 |
| Inventory Days | 177 | 123 | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | 3 | 18 |
| Days Payable | 43 | 33 | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash Conversion Cycle | 205 | 156 | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 107 | 65 |
| Working Capital Days | 166 | 134 | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 101 | 77 |
| ROCE % | 10% | 10% | 15% | 17% | 13% | 7% | 7% | 9% | 7% | 8% | 6% | 12% |
| Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.42% | 71.80% | 71.80% | 70.11% | 69.09% | 68.24% | 68.69% | 68.77% | 69.29% | 71.20% | 72.19% | 73.02% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.85% | 0.85% | 1.33% | 1.33% | 0.48% | 0.61% | 0.61% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.89% | 0.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 29.58% | 28.20% | 28.20% | 29.89% | 30.07% | 30.91% | 29.09% | 29.02% | 30.23% | 28.18% | 27.20% | 26.99% |
| No. of Shareholders | 156 | 106 | 90 | 126 | 126 | 146 | 134 | 152 | 315 | 316 | 301 | 280 |
Fundamentals
Market Cap₹ 37.3 Cr.
Current Price₹ 49.4
Stock P/E12.2
Book Value₹ 43.9
ROCE12.1 %
ROE9.67 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)31%
Compounded Profit Growth (TTM)330%
Standalone figures.
Valuation
Market capRs 37 Cr
Enterprise valueRs 51 Cr
P/E (TTM)12.22x
Price to book1.12x
Price to sales0.32x
EV / EBITDA7.04x
EV / EBIT8.31x
EV / sales0.44x
Price to cash flow4.03x
Earnings yield8.18%
P/E, 3-year average33.43x
P/B, 3-year average1.49x
P/E, 5-year average57.61x
P/B, 5-year average2.07x
Profitability
Operating margin (excl. other income)3.31%
Operating margin (incl. other income)6.19%
EBITDA margin6.19%
Pre-tax margin3.53%
Net profit margin2.62%
ROE9.67%
ROCE12.14%
ROA3.12%
ROE, 3-year average6.00%
ROCE, 3-year average8.86%
ROA, 3-year average1.95%
ROE, 5-year average4.88%
ROCE, 5-year average8.46%
ROA, 5-year average1.66%
ROIC (approx.)9.72%
Tax rate25.85%
Other income / net worth10.11%
Growth
Sales growth (latest year)30.92%
Profit growth (latest year)254.65%
Sales CAGR, 3 years-0.96%
Sales CAGR, 5 years10.46%
Profit CAGR, 3 years49.65%
Profit CAGR, 5 years74.22%
Per share
EPS (TTM)Rs 4.04
EPS (latest year)Rs 4.04
EPS, 3-year averageRs 2.40
EPS, 5-year averageRs 1.90
Book value per shareRs 43.91
Sales per shareRs 154.10
Cash flow per shareRs 12.25
Free cash flow per shareRs 10.60
Efficiency
Asset turnover1.23x
Fixed asset turnover44.38x
Inventory turnover20.09x
Inventory days18 days
Debtor days171 days
Debtors turnover2.13x
Creditor days124 days
Cash conversion cycle65 days
Working capital days77 days
Leverage
Total debtRs 17 Cr
Cash and bankRs 3 Cr
Net debtRs 13 Cr
Debt to equity0.50x
Net debt / EBITDA1.86x
Interest coverage3.05x
Owners' fund to total sources35.17%
Debt to assets17.53%
Cash flow
Cash from Operating Activity (latest year)Rs 9 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs -6 Cr
Net Cash Flow (latest year)Rs 2 Cr
Free cash flow (latest year)Rs 8 Cr
FCFE (approx.: FCF + change in debt)Rs 4 Cr
Cash from ops / profit, 5 years3.25x
Sales to cash flow12.58x
Statement figures
Net sales (TTM)Rs 116 Cr
Net sales (latest year)Rs 116 Cr
Operating profit excl. other income (latest year)Rs 4 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 7 Cr
PBDT (TTM)Rs 5 Cr
Profit before tax (TTM)Rs 4 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 3 Cr
Net profit (latest year)Rs 3 Cr
Depreciation (TTM)Rs 1 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 94 Cr
Total expenditure (latest year)Rs 112 Cr
Total income (latest year)Rs 120 Cr
Share capitalRs 8 Cr
ReservesRs 26 Cr
Shareholders' fundsRs 33 Cr
Total assetsRs 94 Cr
Net blockRs 3 Cr
InvestmentsRs 2 Cr
ReceivablesRs 55 Cr
InventoryRs 5 Cr
Other liabilitiesRs 45 Cr
Shares outstanding (crore)0.75
Ownership
Promoter holding73.02% (+4.25 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 12.2 is at the 3th percentile of its own 6.2-year range
(median 92.0, low 9.4, high 385.4).
P/B 1.13 is at the 14th percentile (median 1.90).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 542934 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +5.1% | -2.8% | +7.9 pts |
| 1 month | +47.0% | -6.8% | +53.8 pts |
| 3 years | -55.1% | +14.2% | -69.3 pts |
| 5 years | -60.3% | +27.9% | -88.2 pts |
Red flags
F-score 8 of 8| look | Profit leans on other income Other income was 82% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹91 Cr -10.8% vs Mar 2024.
Net profit ₹3 Cr +200.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd (542934) has a market capitalisation of Rs 37.3 Cr. at the 2026-09-28 close.
What is the P/E ratio of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd trades at a P/E of 12.2 on trailing twelve-month profit, at the 2026-09-28 close.
What were Chandra Bhagat Pharma Ltd's latest quarterly results?
In the Mar 2026 quarter, Chandra Bhagat Pharma Ltd sales was Rs 91 Cr (-10.8% vs Mar 2024) and net profit was Rs 3 Cr.